Concepedia

John L. Gilmore

JL

Statistics

Publications

20

Citations

661

H-Index

16

Active since

1994

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Ironwood Pharmaceuticals (United States)

Pfizer (United States)

John L. Gilmore is an author at Bristol-Myers Squibb (United States) specializing in drug discovery, medicinal chemistry, and pharmacology.

ORCID

Publications per year

1994–2019

20

Publications

20

2-Amino-4<i>H</i>-3,1-benzoxazin-4-ones as Inhibitors of C1r Serine Protease

Sheryl J. Hays, Bradley W. Caprathe, John L. Gilmore et al. · Journal of Medicinal Chemistry · 1998 · 158 citations · Full text

, , +12

The design and synthesis of sulfonamides as caspase-1 inhibitors

William G. Harter, Hans Albrect, Kenneth D. Brady et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 57 citations · Full text

, , +9

Synthesis and structure–activity relationship of a novel, achiral series of TNF-α converting enzyme inhibitors

John L. Gilmore, Bryan W. King, Cathy Harris et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 47 citations · Full text

, , +16

Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-α converting enzyme (TACE)

James E. Sheppeck, John L. Gilmore, Andrew J. Tebben et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 42 citations · Full text

, , +5

Synthesis and evaluation of 2-aryl-4H-3,1-benzoxazin-4-ones as C1r serine protease inhibitors

John L. Gilmore, Sheryl J. Hays, Bradley W. Caprathe et al. · Bioorganic & Medicinal Chemistry Letters · 1996 · 40 citations

, , +8

1–5 of 20